Advertisement
Research Article| Volume 32, ISSUE 11, P1055-1061, December 01, 1992

Effect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects

DOI:https://doi.org/10.1016/0006-3223(92)90068-B
Effect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects
Previous ArticlePlasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients
Next ArticleErratum
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      In view of the abundant anatomical and functional interactions between serotonin and dopamine systems, this study examined the effect of the serotonin agonist, m-chlorophenylpiperazine (mCPP) on plasma concentrations of the dopamine metabolite, homovanillic acid. Plasma prolactin levels, body temperature, and mCPP blood level were also measured. mCPP (0.35 mg/kg) and placebo were administered orally to 10 healthy men in a randomized double-blind design. Variables were measured for 210 min after administration of capsules. mCPP raised prolactin and temperature as compared to placebo, but did not affect plasma homovanillic acid concentrations. Results suggest that mCPP does not alter dopamine function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Bacopoulos N.G.
        • Hattox S.E.
        • Roth R.H.
        3,4 Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of dopaminergic activity.
        Eur J Pharmacol. 1979; 56: 225-236
        • Cutler N.R.
        • Jeste D.V.
        • Karoum F.
        • Wyatt R.J.
        Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients.
        Life Sci. 1981; 30: 753-756
        • Davidson M.
        • Losonzy M.F.
        • Mohs R.C.
        • et al.
        Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
        Neuropsychopharmacology. 1987; 1: 17-23
        • Davidson M.
        • Kahn R.S.
        • Knott P.
        • et al.
        The effect of neuroleptic treatment on plasma homovanillic acid concentrations and schizophrenic symptoms.
        Arch Gen Psychiatry. 1991; 48: 73-76
        • Davila R.
        • Zumarraga M.
        • Perea K.
        • Andea I.
        Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
        Arch Gen Psychiatry. 1987; 44: 837-838
        • Davila R.
        • Manero E.
        • Zumarraga-Andia I.
        • Schweitzer J.W.
        • Friedhoff A.J.
        Plasma homovanillic acid as a predictor of response to neuroleptic.
        Arch Gen Psychiatry. 1988; 45: 564-567
        • Doran A.R.
        • Pickar D.
        • Labarca R.
        • et al.
        Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients.
        Psychopharmacol Bull. 1985; 21: 694-697
        • Hamik A.
        • Peroutka S.J.
        1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.
        Biol Psychiatry. 1989; 25: 569-575
        • Jenner P.
        • Sheehy M.
        • Marsden C.D.
        Noradrenaline and 5-hydroxytrytamine modulation of brain dopamine function: implications for the treatment of parkinsons disease.
        Br J Clin Pharmacol. 1983; 15: 277S-289S
        • Kahn R.S.
        • Wetzler S.
        m-Chlorophenylpiperazine as a probe of serotonin receptors: A review.
        Biol Psychiatry. 1991; 30: 1139-1166
        • Kahn R.S.
        • Wetzler S.
        • Asnis G.M.
        • van Praag H.M.
        Effects of m-chlorophenylpiperazine in normal subjects: A dose-response study.
        Psychopharmacology. 1990; 100: 339-344
        • Kahn R.S.
        • Wetzler S.
        • Asnis G.M.
        • van Praag H.M.
        Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.
        Psychiatry Res. 1991; 37: 25-34
        • Kahn R.S.
        • Siever L.
        • Gabriel S.
        • et al.
        Serotonin function in schizophrenia: Effect of m-chlorophenylpiperazine in schizophrenic patients and healthy subjects.
        Psychiatry Res. 1992; 43: 1-12
        • Kelland M.D.
        • Freeman A.S.
        • Chiodo L.A.
        Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons.
        J Pharm Exp Ther. 1990; 255: 803-811
        • Kendler K.S.
        • Davis K.L.
        Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat.
        Psychiatry Res. 1984; 13: 51-56
        • Kendler K.S.
        • Heninger G.R.
        • Roth R.H.
        Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.
        Eur J Pharmacol. 1981; 71: 321-326
        • Kendler K.S.
        • Heninger G.R.
        • Roth R.H.
        Influence of dopamine agonists on plasma and brain levels of homovanillic acid.
        Life Sci. 1982; 30: 2063-2069
        • Lambert G.W.
        • Eisenhofer G.
        • Cox H.S.
        • et al.
        Direct determination of homovanillic acid release from the human brain, an indicator of central dopaminergic activity.
        Life Sci. 1991; 49: 1061-1072
        • Maas J.W.
        • Contreras S.A.
        • Bowden C.L.
        • Weintraub S.E.
        Effects of debrisoquin on CSF and plasma HVA concentrations in man.
        Life Sci. 1985; 36: 2163-2170
        • Mueller E.A.
        • Sunderland T.
        • Murphy D.L.
        Neuroendocrine effects of m-CPP, a serotonin agonist, in humans.
        J Clin Endocrinol Metab. 1985; 61: 1179-1184
        • Murphy D.L.
        • Mueller E.A.
        • Hill J.L.
        • Tolliver T.J.
        • Jacobsen F.M.
        Comparative anxiogenic,neuroendocrine, and other physiologic effects of m-Chlorophenylpiperazine given intravenously or orally to healthy volunteers.
        Psychopharmacology. 1989; 98: 275-282
        • Pickar D.
        • Labarca R.
        • Doran A.
        • et al.
        Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients.
        Arch Gen Psychiatry. 1986; 43: 669-676
        • Sack D.A.
        • James S.P.
        • Doran A.R.
        • Sherer M.A.
        • Linnoila M.
        • Wehr T.A.
        The diurnal variation in plasma homovanillic acid levels persists but the variations in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions.
        Arch Gen Psychiatry. 1988; 45: 162-166
        • Suckow R.F.
        • Cooper Th.B.
        • Kahn R.S.
        High-performance liquid chromatographic method for analysis of plasma m-chlorophenylpiperazine.
        J Chromotogr. 1990; 528: 228-234
        • Törk I.
        Anatomy of the serotonergic system.
        Ann NY Acad Sci. 1991; 600: 9-34

      Article info

      Publication history

      Received in revised form: August 22, 1992
      Received: May 4, 1992

      Identification

      DOI: https://doi.org/10.1016/0006-3223(92)90068-B

      Copyright

      © 1992 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX